ACE Inhibitors and ARBs in Diabetic Patients Without Hypertension

Introduction to ACE Inhibitors and ARBs

The American Diabetes Association recommends against prescribing ACE inhibitors or ARBs to patients with diabetes who lack both hypertension and kidney disease, as clinical trials show no benefit in preventing diabetic kidney disease and one trial demonstrated increased cardiovascular events 1, 2

Measure spot urinary albumin-to-creatinine ratio (UACR) and eGFR in all diabetic patients annually, according to the American Diabetes Association 3
The American Diabetes Association explicitly states that ACE inhibitors or ARBs are not recommended for patients without hypertension to prevent the development of chronic kidney disease 1, 2
In type 1 diabetic patients without albuminuria or hypertension, ACE inhibitors or ARBs did not prevent the development of diabetic glomerulopathy on kidney biopsy 1, 2
In type 2 diabetic patients with normal urinary albumin excretion, an ARB actually increased the rate of cardiovascular events despite reducing albuminuria development 1, 2, 3

For patients with no kidney disease (UACR <30 mg/g and eGFR ≥60 mL/min/1.73 m²), do not prescribe ACE inhibitors or ARBs 1, 2, 4
For patients with moderate albuminuria (UACR 30-299 mg/g), consider prescribing ACE inhibitor or ARB at maximum tolerated dose even without hypertension 1, 2, 4
For patients with severe albuminuria (UACR ≥300 mg/g) and/or reduced eGFR (<60 mL/min/1.73 m²), strongly prescribe ACE inhibitor or ARB as first-line therapy regardless of blood pressure status 1, 2, 4, 5, 3

Monitor serum creatinine/eGFR and serum potassium within 2-4 weeks of initiation or dose change, then at least annually, as recommended by the American Diabetes Association 5, 3

Never combine ACE inhibitors and ARBs, as two clinical trials found no benefits on cardiovascular or kidney disease outcomes and combination therapy had higher adverse event rates including hyperkalemia and acute kidney injury 1, 2, 4
Do not prescribe these medications solely for "cardioprotection" in diabetic patients without kidney disease or hypertension, as absent kidney disease, ACE inhibitors or ARBs are not superior to thiazide-like diuretics or dihydropyridine calcium channel blockers 1, 2, 3
Watch for hyperkalemia risk, especially with coadministration with potassium-sparing diuretics, NSAIDs, or in patients with reduced eGFR, and monitor serum potassium frequently in high-risk patients 5

The strongest guideline evidence comes from the 2019 American Diabetes Association Standards of Medical Care and the 2022 ADA Cardiovascular Disease guidelines, which consistently state that ACE inhibitors or ARBs are not recommended for patients without hypertension to prevent the development of chronic kidney disease 1, 2, 4, 5